Pricing Log in Create free account
Friday 6 November 2026 Export GMAB’s income statement to Excel — free account

Genmab A/S Sponsored ADR

GMAB Healthcare Biotechnology

Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.

Revenue
+24.9%
EPS
−9.26%
Free cash flow
−7.69%

Quarter to June 2026, against a year earlier

53.58 0.84 +1.59%
Market cap
$31.5B
P/E
41.7×
Fwd P/E
47.3×
Dividend yield
—
F-score
4/9
Altman Z
2.78
Beneish M
−3.00
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Genmab A/S Sponsored ADR (GMAB) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, Genmab A/S Sponsored ADR (GMAB) trades at a EV/EBITDA of 31.0×. Over the past ten years it has ranged from 0.0× (September 2019) to 57.3× (September 2021); the current reading is higher than 76% of that period. That is above the Biotechnology industry median of 0.7× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 20.0× 95.40%
FY2024 10.2× (53.52%)
FY2023 22.0× (20.97%)
FY2022 27.8× (41.52%)
FY2021 47.6× 91.12%
FY2020 24.9× 21.28%
FY2019 20.5× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period EV/EBITDA Change
Jun 2026 17.6× (2.78%)
Mar 2026 18.1× (9.59%)
Dec 2025 20.0× 77.36%
Sep 2025 11.3× 39.28%
27 more quarters

Against its own ten years

Low 0.0× High 57.3×
Ten-year median 19.3×
Current reading's percentile 76

EV/EBITDA against peers

Company EV/EBITDA
ROIV Roivant Sciences Ltd. compare n/m
BNTX BioNTech SE Sponsored ADR compare n/m
RVMD Revolution Medicines, Inc. compare n/m
INSM Insmed, Inc. compare n/m
ALNY Alnylam Pharmaceuticals, Inc. compare 17.8×
RPRX Royalty Pharma PLC compare 24.7×
INCY Incyte Corporation compare 27.9×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 28.6×
GMAB Genmab A/S Sponsored ADR 31.0×
Biotechnology industry median 0.7×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on GMAB